I Ibsen said that its new drug (Ercirfo), which was recently adopted, could become the first drug alternative to cultivating liver for patients with the primary scaling bile ducts, which destroys the bile ducts inside and outside the liver.
The company intends to announce the results of the average stage of its experience of the drug (Erckerfu) during the meeting of the European League for the Study of Liver in Amsterdam next month.
During a 12 -week study, 68 patients with inflammation of the initial scrap bile ducts (Ercirfo) received daily doses 80 or 120 milligrams.
And the patients, who received the drug, were noticeable in liver enzyme levels starting from the fourth week, with greater effects appearing when the doses are increased.
And blood tests showed that liver fibrosis settled more among the patients who received the medicine, while others who received higher doses mentioned that they felt a significant decline in their sense of itching, which is a symptom of the disease.
It is believed that the drug works by stimulating molecules in the body that regulate the treatment of fatty acids and inhibit the synthesis of bile acids.
“The results are encouraging.”
“The infection of the primary solid bile ducts is a serious disease that affects the liver, and the liver is currently implanting is the only treatment that can significantly improve the condition,” she added.
But she stressed the need to conduct wider experiments to continue to assess the effect of the drug on people with the disease.